Astellas Pharma Revenue 2012-2019 | ALPMY

Astellas Pharma annual/quarterly revenue history and growth rate from 2012 to 2019. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Astellas Pharma revenue for the quarter ending September 30, 2019 was $M, a 100% decline year-over-year.
  • Astellas Pharma revenue for the twelve months ending September 30, 2019 was $8.971B, a 25.07% decline year-over-year.
  • Astellas Pharma annual revenue for 2019 was $11.757B, a 4.16% decline from 2018.
  • Astellas Pharma annual revenue for 2018 was $12.267B, a 4.75% increase from 2017.
  • Astellas Pharma annual revenue for 2017 was $11.711B, a 2.79% increase from 2016.
Astellas Pharma Annual Revenue
(Millions of US $)
2019 $11,757
2018 $12,267
2017 $11,711
2016 $11,393
2015 $11,350
2014 $11,067
2013 $10,698
2012 $11,822
2011 $11,791
2010 $10,519
2009 $9,947
2008 $9,395
2007 $7,650
2006 $7,993
Astellas Pharma Quarterly Revenue
(Millions of US $)
Q2 2019
Q1 2019 $3,041
Q1 2018 $3,028
Q1 2017 $2,903
Q2 2016 $3,076
Q1 2016 $3,141
Q4 2016 $2,655
Q3 2015 $3,101
Q2 2015 $2,819
Q1 2015 $2,818
Q4 2015 $2,431
Q3 2014 $3,153
Q2 2014 $2,873
Q1 2014 $2,893
Q4 2014
Q3 2013
Q2 2013
Q1 2013 $2,786
Q4 2013
Q3 2012
Q2 2012
Q1 2012 $3,040
Q4 2012
Q3 2011
Sector Industry Market Cap Revenue
Medical Medical - Drug Manufacturing $32.724B $11.834B
Astellas Pharma, Inc. is engaged in the research, development, manufacturing and marketing of pharmaceuticals drugs. Products offered by the Company include Prograf applicable for the prevention of rejection in organ transplants, Vesicare for treatment of overactive bladder, Protopic for the treatment of atopic dermatitis in the topical immunomodulator class, Harnal to treat the functional symptoms of benign prostatic hyperplasia (BPH), including weak urinary stream, frequent nighttime urination, and sensation of incomplete emptying of the bladder and Fungard an antifungal agent. Astellas Pharma, Inc. is headquartered in Tokyo, Japan.
Stock Name Country Market Cap PE Ratio
Zoetis (ZTS) United States $66.758B 39.93
Takeda Pharmaceutical (TAK) Japan $62.374B 9.86
Eisai (ESALY) Japan $21.612B 41.66
Merck (MKGAF) Germany $16.401B 22.38
Grifols, S.A (GRFS) Spain $16.254B 21.30
Neurocrine Biosciences (NBIX) United States $9.639B 455.09
Ono Pharmaceutical (OPHLF) Japan $9.450B 20.20
Catalent (CTLT) United States $8.907B 36.24
Jazz Pharmaceuticals (JAZZ) Ireland $8.545B 10.91
Ionis Pharmaceuticals (IONS) United States $8.458B 17.13
Recordati Industria Chimica E Farmaceutica S.P.A (RCDTF) Italy $8.449B 0.00
IPSEN SA ADR (IPSEY) France $7.617B 0.00
STADA ARZNEIMI (STDAF) Germany $6.004B 0.00
Hikma Pharmaceuticals Plc (HKMPF) United Kingdom $5.990B 0.00
Orion OYJ (ORINY) Finland $5.849B 30.12
Hypermarcas (HYPMY) Brazil $5.646B 17.17
Arrowhead Pharmaceuticals (ARWR) United States $5.400B 81.77
Evotec AG (EVTCY) Germany $4.191B 67.73
United Therapeutics (UTHR) United States $4.087B 0.00
Sage Therapeutics (SAGE) United States $3.959B 0.00
Nektar Therapeutics (NKTR) United States $3.955B 0.00
FibroGen (FGEN) United States $3.870B 113.72
PTC Therapeutics (PTCT) United States $3.316B 0.00
Taro Pharmaceutical Industries (TARO) Israel $3.273B 12.05
ChemoCentryx (CCXI) United States $2.534B 0.00
Zogenix (ZGNX) United States $2.433B 0.00
Aurinia Pharmaceuticals Inc (AUPH) Canada $2.150B 0.00
Xencor (XNCR) United States $2.130B 64.74
Tilray (TLRY) Canada $2.108B 0.00
Ironwood Pharmaceuticals (IRWD) United States $1.976B 63.00
Heron Therapeutics (HRTX) United States $1.941B 0.00
Pacira Pharmaceuticals (PCRX) United States $1.829B 54.10
USANA Health Sciences (USNA) United States $1.760B 18.78
AMNEAL PHARMACEUTICALS, INC (AMRX) United States $1.525B 10.41
CLINIGEN GP (CLIGF) United Kingdom $1.506B 0.00
Corcept Therapeutics (CORT) United States $1.474B 17.92
Theravance Biopharma (TBPH) Cayman Islands $1.432B 0.00
Endo (ENDP) Ireland $1.370B 2.52
Enanta Pharmaceuticals (ENTA) United States $1.143B 26.10
Portola Pharmaceuticals (PTLA) United States $1.118B 0.00
Karyopharm Therapeutics (KPTI) United States $1.070B 0.00
Aerie Pharmaceuticals (AERI) United States $1.053B 0.00
Dermira (DERM) United States $1.044B 0.00
Akebia Therapeutics (AKBA) United States $0.955B 0.00
Radius Health (RDUS) United States $0.907B 0.00
Collegium Pharmaceutical (COLL) United States $0.785B 0.00
ImmunoGen (IMGN) United States $0.683B 0.00
Flexion Therapeutics (FLXN) United States $0.668B 0.00
TherapeuticsMD (TXMD) United States $0.626B 0.00
Crinetics Pharmaceuticals (CRNX) United States $0.576B 0.00
Molecular Templates (MTEM) United States $0.507B 0.00
Organogenesis Holdings (ORGO) United States $0.501B 0.00
DURECT (DRRX) United States $0.483B 0.00
Rigel Pharmaceuticals (RIGL) United States $0.483B 0.00
Translate Bio (TBIO) United States $0.483B 0.00
Ardelyx (ARDX) United States $0.470B 0.00
Corbus Pharmaceuticals Holdings (CRBP) United States $0.453B 0.00
Innate Pharma SA (IPHYF) France $0.438B 0.00
Catalyst Pharmaceuticals (CPRX) United States $0.429B 52.00
Siga Technologies (SIGA) United States $0.422B 9.63
BioSpecifics Technologies Corp (BSTC) United States $0.419B 18.08
Aptorum Group (APM) Hong Kong, SAR China $0.418B 0.00
BioCryst Pharmaceuticals (BCRX) United States $0.412B 0.00
Calithera Biosciences (CALA) United States $0.398B 0.00
Lannett Co Inc (LCI) United States $0.393B 4.58
Spectrum Pharmaceuticals (SPPI) United States $0.366B 0.00
Recro Pharma (REPH) United States $0.366B 0.00
Harpoon Therapeutics (HARP) United States $0.357B 0.00
OptiNose (OPTN) United States $0.356B 0.00
Indivior (INVVY) United States $0.335B 1.21
KalVista Pharmaceuticals (KALV) United States $0.331B 0.00
Rafael Holdings (RFL) United States $0.325B 0.00
Foamix Pharmaceuticals (FOMX) Israel $0.289B 0.00
Avadel Pharmaceuticals (AVDL) Ireland $0.286B 0.00
MEI Pharma (MEIP) United States $0.256B 0.00
Concert Pharmaceuticals (CNCE) United States $0.248B 0.00
Concordia (CXRXF) Canada $0.248B 0.00
Jounce Therapeutics (JNCE) United States $0.241B 3.22
Ocular Therapeutix (OCUL) United States $0.223B 0.00
La Jolla Pharmaceutical (LJPC) United States $0.210B 0.00
IMV INC (IMV) Canada $0.203B 0.00
Nature's Sunshine Products (NATR) United States $0.188B 32.43
Taiwan Liposome (TLC) Taiwan $0.170B 0.00
Xeris Pharmaceuticals (XERS) United States $0.167B 0.00
CannTrust Holdings (CTST) Canada $0.167B 0.00
AcelRx Pharmaceuticals (ACRX) United States $0.151B 0.00
MARKER THERAPEUTICS, INC (MRKR) United States $0.146B 0.00
Galmed Pharmaceuticals (GLMD) Israel $0.135B 0.00
Redhill Biopharma (RDHL) Israel $0.134B 0.00
CV Sciences (CVSI) United States $0.125B 0.00
Bellicum Pharmaceuticals (BLCM) United States $0.114B 0.00
Oasmia Pharmaceutical AB (OASMY) Sweden $0.114B 0.00
Otonomy (OTIC) United States $0.110B 0.00
PolarityTE (PTE) United States $0.108B 0.00
ALLERGY THERAPT (AGYTF) United Kingdom $0.108B 0.00
Aquestive Therapeutics (AQST) United States $0.103B 0.00
ASSERTIO THERAPEUTICS, INC (ASRT) United States $0.100B 0.00
Champions Oncology (CSBR) United States $0.098B 0.00
MediWound (MDWD) Israel $0.082B 0.00
CTI BioPharma (CTIC) United States $0.080B 0.00
Neos Therapeutics (NEOS) United States $0.080B 0.00
Cumberland Pharmaceuticals (CPIX) United States $0.077B 23.18
Aclaris Therapeutics (ACRS) United States $0.076B 0.00
Infinity Pharmaceuticals (INFI) United States $0.067B 0.00
Natural Alternatives (NAII) United States $0.066B 16.52
Entasis Therapeutics Holdings (ETTX) United States $0.064B 0.00
Nivalis Therapeutics (ALPN) United States $0.063B 0.00
SCYNEXIS (SCYX) United States $0.062B 0.00
RENEURON GP (RNUGF) United Kingdom $0.061B 0.00
Onconova Therapeutics (ONTX) United States $0.057B 0.00
Opiant Pharmaceuticals (OPNT) United States $0.055B 0.00
Summit Therapeutics (SMMT) United Kingdom $0.050B 0.00
Adamis Pharmaceuticals (ADMP) United States $0.048B 0.00
Iterum Therapeutics (ITRM) Ireland $0.046B 0.00
Jaguar Animal Health (JAGX) United States $0.045B 0.00
Forward Pharma (FWP) Denmark $0.044B 0.00
Dipexium Pharmaceuticals (PLXP) United States $0.043B 0.00
ElectroCore (ECOR) United States $0.041B 0.00
Mannatechorporated (MTEX) United States $0.038B 0.00
Biomerica (BMRA) United States $0.029B 0.00
PharmAthene (ALT) United States $0.028B 0.00
Eyegate Pharmaceuticals (EYEG) United States $0.028B 0.00
Regulus Therapeutics (RGLS) United States $0.025B 0.00
China SXT Pharmaceuticals (SXTC) China $0.024B 0.00
Bio-Path Holdings (BPTH) United States $0.022B 0.00
ProPhase Labs (PRPH) United States $0.021B 0.00
Cardiome Pharma (CORV) Canada $0.019B 0.00
VAXART, INC (VXRT) United States $0.018B 0.00
Shineco (TYHT) China $0.018B 0.00
Novan (NOVN) United States $0.017B 0.00
Kitov Pharmaceuticals Holdings (KTOV) Israel $0.016B 0.00
Cyanotech (CYAN) United States $0.015B 0.00
Lipocine (LPCN) United States $0.013B 0.00
Flex Pharma (SLRX) United States $0.013B 0.00
Vical (BBI) United States $0.013B 0.00
Heat Biologics (HTBX) United States $0.012B 0.00
HANCOCK JAFFE (HJLI) United States $0.011B 0.00
Cytori Therapeutics Inc (PSTV) United States $0.010B 0.00
Tetraphase Pharmaceuticals (TTPH) United States $0.009B 0.00
Sonoma Pharmaceuticals (SNOA) United States $0.007B 0.00
RXi Pharmaceuticals (PHIO) United States $0.007B 0.00
Xenetic Biosciences (XBIO) United States $0.006B 0.00
Midatech Pharma (MTP) United Kingdom $0.003B 0.00